ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Calidi Biotherapeutics Inc

Calidi Biotherapeutics Inc (CLDI)

1.7383
0.0383
( 2.25% )
Updated: 10:54:54

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
1.7383
Bid
-
Ask
-
Volume
142,726
1.73 Day's Range 1.82
1.414 52 Week Range 50.00
Market Cap
Previous Close
1.70
Open
1.77
Last Trade
1
@
1.74
Last Trade Time
10:59:46
Financial Volume
$ 251,654
VWAP
1.7632
Average Volume (3m)
1,328,214
Shares Outstanding
6,419,114
Dividend Yield
-
PE Ratio
-0.38
Earnings Per Share (EPS)
-4.55
Revenue
-
Net Profit
-29.22M

About Calidi Biotherapeutics Inc

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the price and yield performance of the FLAGLSX-Forensic Accounting Long-Short Index. The investment seeks to provide investment results that, before fees and expenses, correspond generally to the price and yield performance of the FLAGLSX-Forensic Accounting Long-Short Index.

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
1970
Calidi Biotherapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the American Stock Exchange with ticker CLDI. The last closing price for Calidi Biotherapeutics was $1.70. Over the last year, Calidi Biotherapeutics shares have traded in a share price range of $ 1.414 to $ 50.00.

Calidi Biotherapeutics currently has 6,419,114 shares outstanding. The market capitalization of Calidi Biotherapeutics is $10.91 million. Calidi Biotherapeutics has a price to earnings ratio (PE ratio) of -0.38.

CLDI Latest News

Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform

SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted...

Calidi to Effect Reverse Stock Split

Calidi common stock expected to begin trading on a 1-for-10 split adjusted basis on July 15, 2024 Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi” or “Company”), a clinical-stage...

Calidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of Directors

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the...

Calidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13

Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, is pleased to...

Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi’s Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors

Calidi’s best-in-class, novel systemic targeted virotherapy program (RTNova) aims to provide a feasible solution to target disseminated tumors with a systemic administration -- a long-pursued...

Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual Meeting

- NeuroNova (CLD-101) Phase 1 update highlights enrollment progress, safety and feasibility in delivering up to four weekly doses of CLD-101 - Showcased preclinical data on RTNova (CLD-400...

 Calidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the...

Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results

Three upcoming posters, including an update from ongoing Phase 1 trial of Calidi’s CLD-101 program, to be presented at 2024 ASCO Annual Meeting Presented new data on the mechanisms of action of...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0717-3.961325966851.811.951.5755965351.69414243CS
4-0.1577-8.317510548521.8962.1981.4149293821.71001568CS
12-0.3077-15.03910068432.0464.91.41413282142.15038141CS
26-8.5617-83.123300970910.316.81.41410855203.14644492CS
52-43.3617-96.145676274945.1501.4146571353.99080135CS
156-43.3617-96.145676274945.1501.4146571353.99080135CS
260-43.3617-96.145676274945.1501.4146571353.99080135CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NUZENuZee Inc
$ 3.09
(200.00%)
75.59M
SLNASelina Hospitality PLC
$ 0.0565
(117.31%)
606.25M
DRMADermata Therapeutics Inc
$ 2.6201
(101.55%)
51.89M
CREVCarbon Revolution Public Ltd
$ 10.82
(73.95%)
150.55k
BBLGBone Biologics Corporation
$ 2.1068
(68.54%)
32.63M
NXTTNext Technology Holding Inc
$ 2.42
(-58.42%)
249.03k
NUWENewellis Inc
$ 2.59
(-37.59%)
673.16k
ATPCAgape ATP Corporation
$ 0.1414
(-34.23%)
3.99M
VWEVintage Wine Estates Inc
$ 0.0799
(-28.60%)
16.38M
CONNConns Inc
$ 0.38
(-25.05%)
2.1M
SLNASelina Hospitality PLC
$ 0.05655
(117.50%)
606.26M
SGMOSangamo Therapeutics Inc
$ 0.5731
(42.81%)
166.21M
NVDANVIDIA Corporation
$ 117.91
(-3.82%)
77.28M
NUZENuZee Inc
$ 3.03
(194.17%)
75.6M
TSLATesla Inc
$ 218.0901
(-11.48%)
73.73M

CLDI Discussion

View Posts
Monksdream Monksdream 4 days ago
CLDI under $2
👍️0
ErnieBilco ErnieBilco 2 weeks ago
Probably because it is a worthless company that is heavily in debt and by all rights it should be kicked off the Nasdaq but Nasdaq urges these worthless companies to screw their shareholders to artificially get their stock price to $1 - I expect a landslide decline back to a quarter in short order.

This is one of my bets that doesn't look like it will make me any money - unless they can somehow pump it up on the fact the the OS will be about 5 million shares on split day.

Just my take on it after looking thru Q1 Quarterly report.
👍️0
JTORENCE JTORENCE 2 weeks ago
Ernie Bilco You may have predicted right. Reverse splits are usually the death blow for a stock. Hope not. Why did they do this??
👍️0
Invest-in-America Invest-in-America 1 month ago
CLDI: News --- collaboration with SIGA to kill all Cancers.
👍️0
Termite7 Termite7 2 months ago
Keeping an eye...... coiled!!!
👍️0
accipiterr accipiterr 2 months ago
April 24th webinar
https://redchip.zoom.us/webinar/register/WN_qT-PBRbTQ0yLeBbJ4jzPSw
in this one they mention 3 different times that they are talking to large pharmaceutical companies about licencing and about how the recent data, specifically for RTnova, has resulted in high level discussions with more planned in the near future.


May 9th webinar
https://sidoti.zoom.us/webinar/register/WN_p8GBAbbqTd2OuYnM33eTuQ#/registration
👍️0
accipiterr accipiterr 2 months ago
Bottom in, looks ready for a move up. Data being presented on June 1st.
👍️0
ErnieBilco ErnieBilco 3 months ago
Yikes, RedChip is usually the kiss of death for all the stocks they have pumped or paid promoted
👍️0
Legend431 Legend431 3 months ago
Looking good
👍️0
Triple nickle Triple nickle 3 months ago
Here we gooooo
👍️0
2020trader 2020trader 3 months ago
DOWN 6% TODAY....EXPECTING LOWER
👍️0
glenn1919 glenn1919 5 months ago
CLDI................................................https://stockcharts.com/h-sc/ui?s=CLDI&p=W&b=5&g=0&id=p86431144783
👍️0

Your Recent History

Delayed Upgrade Clock